Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

Jane Meisel, MD, emphasizes the growing role of real-world evidence in guiding therapy sequencing for HER2+ metastatic breast cancer due to rapidly evolving treatment standards.